The current study provides an example of how a better mechanistic understanding may contribute to this in that it not only uncovers an on-target adverse effect of IDO1 inhibition but also raises the possibility that pharmacologic MITF intervention might be explored to improve immunotherapy outcome of patients with melanoma. The gene discussed is IDO1; the disease is melanoma.